PGM1 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the human Burkitt lymphoma B lymphocyte line, Raji, designed to ablate phosphoglucomutase 1 (PGM1) function. This product provides a genetically heterogeneous pool of PGM1-null cells, enabling robust loss-of-function studies without the clonal biases inherent in single-cell-derived lines. The polyclonal format preserves the biological variability of a knockout population, making it particularly suitable for investigating the multifaceted roles of PGM1 in B cell lymphoma biology, glycosylation, and metabolic reprogramming. By disrupting glucose-1-phosphate interconversion, the model offers a versatile platform for dissecting the intersection between central carbon metabolism and immune cell function.
The Raji cell line, an Epstein-Barr virus (EBV)-positive immortalized B lymphocyte originating from a Burkitt lymphoma patient, serves as a widely utilized model for B cell malignancies, viral latency, and humoral immune responses. These cells retain key features of germinal center B cells, including surface immunoglobulin expression and robust proliferative capacity, while also exhibiting characteristic glycosylation profiles critical for malignant transformation and immune evasion. The EBV-driven latency III program in Raji cells upregulates numerous glycoproteins and adhesion molecules, making them particularly sensitive to perturbations in the glycosylation machinery. Consequently, PGM1 knockout in this background provides a physiologically relevant system to explore how altered glucose-1-phosphate flux impacts oncogenic signaling, antigen presentation, and therapeutic vulnerabilities in aggressive B cell lymphomas.
PGM1 encodes a phosphoglucomutase that catalyzes the reversible conversion of glucose-1-phosphate to glucose-6-phosphate, a reaction pivotal for glycogen synthesis, galactose utilization, and the generation of UDP-glucose, the universal sugar donor for glycosylation. Within the broader metabolic network, PGM1 is transcriptionally regulated by PGC-1?? (PPARGC1A) downstream of insulin/IGF-1, glucagon, and AMPK signaling, and its activity is substrate-limited by glucose-1-phosphate availability. The enzyme forms functional complexes with glycogenin and glycogen synthase (GYS1) during glycogenesis, and operates in tandem with UDP-glucose pyrophosphorylase (UGP2), galactose-1-phosphate uridylyltransferase (GALT), and the paralog phosphoglucomutase 2 (PGM2). Downstream, PGM1-derived glucose-6-phosphate feeds into glycolysis and the pentose phosphate pathway, while UDP-glucose drives N-glycan and glycosaminoglycan biosynthesis via gylcosyltransferases dependent on the GALE/PGM3 axis. Disruption of PGM1 thus uncouples glycogen storage, galactose catabolism, and glycoconjugate production, with the mechanistic consequence of diminished UDP-glucose pools and aberrant glycosylation patterns.
In the Raji context, PGM1 knockout directly compromises the synthesis of complex N-glycans and glycosaminoglycans, leading to altered cell-surface architecture and impaired immune synapse formation. Key B cell receptors such as CD19 and CD20, which rely on extensive glycosylation for stability and signaling, can exhibit reduced expression or aberrant processing, potentially affecting proliferative capacity and apoptosis sensitivity. This glycosylation defect also models the pathophysiology of PGM1 deficiency, a congenital disorder of glycosylation (type It) manifesting as glycogen storage disease type XIV with myopathy, cardiomyopathy, hypoglycemia, and growth retardation. By coupling a metabolic enzyme lesion with a lymphoma background, the knockout cells provide a unique tool to examine how nutrient-sensing and glycosylation intersect to govern malignant B cell behavior, offering insights into tumor-specific metabolic dependencies and immune recognition.
Researchers can employ these polyclonal knockout cells in a diverse array of applications, including modeling glycogen storage disorders and congenital disorders of glycosylation, probing the role of glycosylation in B cell activation and cancer metabolism, and screening small-molecule correctors for PGM1 deficiency. Typical assays capitalize on the cells?? robust growth and glycosylation phenotype: periodic acid?CSchiff (PAS) staining for glycogen accumulation, lectin blotting with concanavalin A or L-PHA to profile N-glycan structures, U-13C glucose metabolic flux analysis to trace carbon partitioning, and flow cytometric quantification of glycosylation-dependent surface markers like CD19 and CD20. Complementary functional approaches include CFSE-based proliferation and Annexin V apoptosis assays, transcriptomic analysis via RNA-seq or targeted RT-qPCR for glycosylation-related genes, and drug sensitivity profiling with glycosylation inhibitors or metabolic rescue agents. For further information or to inquire about pricing, please contact Ascent Research at [email protected].
